Logo image of EXEL

EXELIXIS INC (EXEL) Stock Fundamental Analysis

USA - NASDAQ:EXEL - US30161Q1040 - Common Stock

39.14 USD
+0.13 (+0.33%)
Last: 9/16/2025, 6:48:13 PM
38.7798 USD
-0.36 (-0.92%)
After Hours: 9/16/2025, 6:48:13 PM
Fundamental Rating

8

Overall EXEL gets a fundamental rating of 8 out of 10. We evaluated EXEL against 540 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making EXEL a very profitable company, without any liquidiy or solvency issues. An interesting combination arises when we look at growth and value: EXEL is growing strongly while it also seems undervalued. These ratings would make EXEL suitable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

EXEL had positive earnings in the past year.
EXEL had a positive operating cash flow in the past year.
In the past 5 years EXEL has always been profitable.
EXEL had a positive operating cash flow in each of the past 5 years.
EXEL Yearly Net Income VS EBIT VS OCF VS FCFEXEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

The Return On Assets of EXEL (22.49%) is better than 97.04% of its industry peers.
EXEL has a Return On Equity of 29.62%. This is amongst the best in the industry. EXEL outperforms 97.22% of its industry peers.
With an excellent Return On Invested Capital value of 25.22%, EXEL belongs to the best of the industry, outperforming 98.15% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for EXEL is significantly below the industry average of 15.95%.
The 3 year average ROIC (10.78%) for EXEL is below the current ROIC(25.22%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 22.49%
ROE 29.62%
ROIC 25.22%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
EXEL Yearly ROA, ROE, ROICEXEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 150

1.3 Margins

Looking at the Profit Margin, with a value of 27.01%, EXEL belongs to the top of the industry, outperforming 96.11% of the companies in the same industry.
EXEL's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 33.71%, EXEL belongs to the best of the industry, outperforming 97.78% of the companies in the same industry.
In the last couple of years the Operating Margin of EXEL has declined.
With an excellent Gross Margin value of 96.59%, EXEL belongs to the best of the industry, outperforming 95.74% of the companies in the same industry.
EXEL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 33.71%
PM (TTM) 27.01%
GM 96.59%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
EXEL Yearly Profit, Operating, Gross MarginsEXEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

9

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), EXEL is creating value.
The number of shares outstanding for EXEL has been reduced compared to 1 year ago.
The number of shares outstanding for EXEL has been reduced compared to 5 years ago.
There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EXEL Yearly Shares OutstandingEXEL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
EXEL Yearly Total Debt VS Total AssetsEXEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 11.80 indicates that EXEL is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 11.80, EXEL belongs to the top of the industry, outperforming 87.78% of the companies in the same industry.
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 11.8
ROIC/WACC2.64
WACC9.57%
EXEL Yearly LT Debt VS Equity VS FCFEXEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B

2.3 Liquidity

A Current Ratio of 3.51 indicates that EXEL has no problem at all paying its short term obligations.
The Current ratio of EXEL (3.51) is comparable to the rest of the industry.
A Quick Ratio of 3.44 indicates that EXEL has no problem at all paying its short term obligations.
With a Quick ratio value of 3.44, EXEL perfoms like the industry average, outperforming 41.85% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.51
Quick Ratio 3.44
EXEL Yearly Current Assets VS Current LiabilitesEXEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

8

3. Growth

3.1 Past

EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.74%, which is quite impressive.
Measured over the past years, EXEL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.65% on average per year.
Looking at the last year, EXEL shows a quite strong growth in Revenue. The Revenue has grown by 10.73% in the last year.
Measured over the past years, EXEL shows a quite strong growth in Revenue. The Revenue has been growing by 17.51% on average per year.
EPS 1Y (TTM)67.74%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%-15.58%
Revenue 1Y (TTM)10.73%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%-10.82%

3.2 Future

The Earnings Per Share is expected to grow by 22.20% on average over the next years. This is a very strong growth
Based on estimates for the next years, EXEL will show a quite strong growth in Revenue. The Revenue will grow by 10.31% on average per year.
EPS Next Y27.76%
EPS Next 2Y25.29%
EPS Next 3Y26.04%
EPS Next 5Y22.2%
Revenue Next Year7.25%
Revenue Next 2Y9.86%
Revenue Next 3Y11.39%
Revenue Next 5Y10.31%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
EXEL Yearly Revenue VS EstimatesEXEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
EXEL Yearly EPS VS EstimatesEXEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 18.82 indicates a rather expensive valuation of EXEL.
94.44% of the companies in the same industry are more expensive than EXEL, based on the Price/Earnings ratio.
EXEL's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.20.
The Price/Forward Earnings ratio is 13.48, which indicates a correct valuation of EXEL.
Based on the Price/Forward Earnings ratio, EXEL is valued cheaper than 95.56% of the companies in the same industry.
EXEL's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.71.
Industry RankSector Rank
PE 18.82
Fwd PE 13.48
EXEL Price Earnings VS Forward Price EarningsEXEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, EXEL is valued cheaply inside the industry as 95.74% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, EXEL is valued cheaper than 96.85% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.97
EV/EBITDA 11.62
EXEL Per share dataEXEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

EXEL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of EXEL may justify a higher PE ratio.
EXEL's earnings are expected to grow with 26.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.68
PEG (5Y)1.49
EPS Next 2Y25.29%
EPS Next 3Y26.04%

More info and screens

0

5. Dividend

5.1 Amount

EXEL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXELIXIS INC

NASDAQ:EXEL (9/16/2025, 6:48:13 PM)

After market: 38.7798 -0.36 (-0.92%)

39.14

+0.13 (+0.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-28 2025-07-28/amc
Earnings (Next)10-27 2025-10-27/amc
Inst Owners95.32%
Inst Owner Change-0.46%
Ins Owners2.23%
Ins Owner Change10.58%
Market Cap10.54B
Analysts77.69
Price Target45.28 (15.69%)
Short Float %6.7%
Short Ratio5.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.5%
Min EPS beat(2)13.99%
Max EPS beat(2)49.01%
EPS beat(4)4
Avg EPS beat(4)21.76%
Min EPS beat(4)10.66%
Max EPS beat(4)49.01%
EPS beat(8)6
Avg EPS beat(8)17.86%
EPS beat(12)9
Avg EPS beat(12)18.64%
EPS beat(16)12
Avg EPS beat(16)38.79%
Revenue beat(2)1
Avg Revenue beat(2)3.15%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)9.31%
Revenue beat(4)2
Avg Revenue beat(4)3.21%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.17%
Revenue beat(12)5
Avg Revenue beat(12)2.6%
Revenue beat(16)7
Avg Revenue beat(16)2.9%
PT rev (1m)-2.16%
PT rev (3m)8.54%
EPS NQ rev (1m)0.01%
EPS NQ rev (3m)2.65%
EPS NY rev (1m)0.62%
EPS NY rev (3m)4.33%
Revenue NQ rev (1m)-0.05%
Revenue NQ rev (3m)-0.01%
Revenue NY rev (1m)-0.63%
Revenue NY rev (3m)-0.29%
Valuation
Industry RankSector Rank
PE 18.82
Fwd PE 13.48
P/S 4.72
P/FCF 13.97
P/OCF 13.65
P/B 5.18
P/tB 5.35
EV/EBITDA 11.62
EPS(TTM)2.08
EY5.31%
EPS(NY)2.9
Fwd EY7.42%
FCF(TTM)2.8
FCFY7.16%
OCF(TTM)2.87
OCFY7.33%
SpS8.28
BVpS7.55
TBVpS7.32
PEG (NY)0.68
PEG (5Y)1.49
Profitability
Industry RankSector Rank
ROA 22.49%
ROE 29.62%
ROCE 32.1%
ROIC 25.22%
ROICexc 38.09%
ROICexgc 39.72%
OM 33.71%
PM (TTM) 27.01%
GM 96.59%
FCFM 33.81%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexcg growth 3Y9.55%
ROICexcg growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 60.32%
Cap/Sales 0.81%
Interest Coverage 250
Cash Conversion 98.79%
Profit Quality 125.2%
Current Ratio 3.51
Quick Ratio 3.44
Altman-Z 11.8
F-Score8
WACC9.57%
ROIC/WACC2.64
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)67.74%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%-15.58%
EPS Next Y27.76%
EPS Next 2Y25.29%
EPS Next 3Y26.04%
EPS Next 5Y22.2%
Revenue 1Y (TTM)10.73%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%-10.82%
Revenue Next Year7.25%
Revenue Next 2Y9.86%
Revenue Next 3Y11.39%
Revenue Next 5Y10.31%
EBIT growth 1Y86.61%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year42.25%
EBIT Next 3Y34.74%
EBIT Next 5Y1.16%
FCF growth 1Y108.65%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y98.36%
OCF growth 3Y20.43%
OCF growth 5Y5.84%